Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Condition:   Esophageal Cancer
Intervention:   Drug: Apatinib+SHR-1210
Sponsor:   The First Affiliated Hospital of Zhengzhou University
Not yet recruiting

https://ift.tt/2SXY77L